Literature DB >> 6423689

Efficacy of CW-Doppler and duplex system examinations for the evaluation of extracranial carotid disease.

M Hennerici, H J Freund.   

Abstract

The efficacy of different ultrasound methods for the detection of extracranial arterial disease (EAD) was evaluated on the basis of the comparison with angiography. High-resolution B-scan imaging combined with a multigated pulsed Doppler flow pattern analysis (Duplex system) achieved the best results for the detection of morphological and hemodynamic changes of nonstenotic lesions and low grade stenosis. However, a technically unsatisfactory examination rate of 19%, the failure to differentiate between total and subtotal carotid occlusions, underestimation of significant stenosis and impracticable vertebral flow studies were disadvantages of the Duplex technique. CW-Doppler examinations proved to be more precise and more reliable for the detection of significant stenosis and occlusions. Since vertebral blood flow studies were impractical with the Duplex system, CW-Doppler provides more comprehensive information about the hemodynamics of cerebral blood supply.

Entities:  

Mesh:

Year:  1984        PMID: 6423689     DOI: 10.1002/jcu.1870120307

Source DB:  PubMed          Journal:  J Clin Ultrasound        ISSN: 0091-2751            Impact factor:   0.910


  3 in total

1.  Prognostic use of ultrasonography in acute non-hemorrhagic carotid stroke.

Authors:  M Camerlingo; L Casto; B Censori; M C Servalli; B Ferraro; A Mamoli
Journal:  Ital J Neurol Sci       Date:  1996-06

2.  High-resolution real-time ultrasound of the carotid bifurcation in patients with hyperactive carotid sinus syndrome.

Authors:  G Wiedemann; J Grötz; H Bewermeyer; V Hossmann; W D Heiss
Journal:  J Neurol       Date:  1985       Impact factor: 4.849

3.  Complications of cerebral angiography in patients with symptomatic carotid territory ischaemia screened by carotid ultrasound.

Authors:  K N Davies; P R Humphrey
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-09       Impact factor: 10.154

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.